SERETIDE ® - Salmeterol and Fluticasone

SERETIDE ® is a drug based on Salmeterol xinafoate and Fluticasone propionate.

THERAPEUTIC GROUP: Adrenergics for aerosols and other antihistamines

Indications SERETIDE ® - Salmeterol and Fluticasone

SERETIDE ® is indicated in the treatment of asthma in patients requiring long-term therapy with corticosteroids and Beta 2 Agonists.

Mechanism of action SERETIDE ® - Salmeterol and Fluticasone

SERETIDE ® is a medicinal specialty that combines two active ingredients that have always been used in the treatment of asthma and chronic obstructive diseases of the respiratory tract, such as a corticosteroid and a Beta 2 agonist.
The first, namely Fluticasone, is a particularly active inhaled corticosteroid, capable of reducing the secretion of inflammatory mediators, controlling the intracellular pathway, supported by Phospholipase A2, useful for the synthesis of prostaglandins, thromboxanes and leukotrienes.
All this takes place in the reduction of the local inflammatory stimulus, and in a clear improvement of the congestive symptoms associated with this condition.
Salmeterol, on the other hand, a selective agonist of Beta 2 adrenergic receptors, is a molecule with an intense bronchodilator activity, thanks to the ability to bind and activate the Beta 2 adrenergic receptors expressed by bronchial smooth muscles, guaranteeing a prolonged action over the time necessary to restore the normal ventilatory skills.

The portion of active ingredients occasionally absorbed systemically, following a hepatic metabolism, will subsequently be eliminated by the kidney.

Studies carried out and clinical efficacy

SERETIDE, ASTHMA AND GENES
Eur Rev Med Pharmacol Sci. 2012 Nov; 16: 1701-6.

Research on the molecular mechanism of Seretide treatment to asthma disease.

Liu ZW, Yue F, Gao FY, Qian YB, Wang RL.


Interesting study that aims to evaluate the molecular mechanisms characterizing the asthmatic pathology, also taking care to characterize the potential therapeutic effect of Seretide against these genetic and molecular pathways. The study focuses on the evaluation of over 400 genes and related molecular cascades in which they are involved.

SALMETEROL AND FLUTICASONE IN SMOKING ASTHMATIC PATIENTS
Chest. 2012 Feb; 141: 330-8. doi: 10.1378 / chest.11-0392. Epub 2011 Jun 2.

Fluticasone / Salmeterol combination confers benefits in people with asthma who smoke.

Clearie KL, McKinlay L, Williamson PA, Lipworth BJ.


Interesting study that demonstrates how the combined treatment with Salmeterol and Fluticasone can optimize the therapeutic response in asthmatic patients and smokers, also ensuring an important action against the bronchial smooth muscle, generally contracted in smoking patients.

FLUTICASONE / SALMETEROL IN COPD PATIENTS
Respir Med. 2013 May; 107: 708-16. doi: 10.1016 / j.rmed.2013.01.009. Epub 2013 Feb 17.

Effect of fluticasone / salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.

Guenette JA, Webb KA, O "Donnell DE.


Work conducted on patients suffering from chronic obstructive pulmonary disease which demonstrates how treatment even for just 6 weeks with Fluticasone and Salmeterol can lead to a marked improvement in symptoms, and in particular in dyspnoea and breathing difficulties during endurance exercise.

Method of use and dosage

SERETIDE ®
Pressurized suspension for inhalation of 25 mcg of Salmeterol and 50, 125 and 250 mcg of Fluticasone propionate per delivery.
Therapy with SERETIDE ® must necessarily be defined and supervised by your doctor, due to the complexity and the enormous inter-individual variability.
In fact, the doctor, after having carefully evaluated the patient's state of health and the severity of his clinical picture, should identify the minimum effective dosage to ensure a remission of the symptoms.
Therefore, although the recommended doses in adults are those of two inhalations per day, it is not possible to define a priori a recommended and effective standard dosage for everyone.

SERETIDE ® Warnings - Salmeterol and Fluticasone

Therapy with SERETIDE ® must necessarily be preceded by a careful medical examination aimed at clarifying the origin of the complained symptoms and the consequent prescribing appropriateness, and subsequently be supervised both in terms of clinical efficacy and safety of use.
However, it is advisable for the doctor to define, together with the basic therapy with SERETIDE ®, also an emergency therapy in case of acute asthmatic attacks, clinically very significant.
Like other topical corticosteroid therapies, even that with SERETIDE ®, especially if prolonged for a long time, could cause local adverse reactions, more frequently, and rarely systemic, such as hyperglycemia or alterations of the hypothalamic-pituitary axis. adrenal.
SERETIDE ® therapy should be carried out with particular caution in patients suffering from kidney disease, diabetes, hypertension, cardiovascular disease and viral, fungal or tuberculous infections.
The use of SERETIDE ®, without clinical necessity, is forbidden in and out of the competition.
It is recommended to store the drug out of the reach of children.


PREGNANCY AND BREASTFEEDING

Since the experimental evidence relating to the use of these active ingredients in pregnancy and during breastfeeding is still quite controversial, it would be correct to extend the aforementioned contraindications to the use of SERETIDE ® also to pregnancy and the subsequent breastfeeding period. breast.
In the above cases, the use of this drug should be justified only by real clinical needs and periodically supervised by your doctor.

Interactions

Although the systemic absorption of the two active ingredients is pharmacologically negligible, it would be advisable for the patient receiving SERETIDE ® to avoid the simultaneous intake of inhibitors or inducers of the cytochromial system, potentially responsible for significant alterations in the pharmacokinetic characteristics of the absorbed portion of Fluticasone and Salmeterol. .
It is also recommended to avoid the simultaneous intake of Beta blockers and Beta adrenergics.

Contraindications SERETIDE ® - Salmeterol and Fluticasone

The use of SERETIDE ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients or to structurally and chemically related molecules.

Undesirable Effects - Side Effects

SERETIDE ® therapy could lead to the onset of candidiasis of the mouth and throat, pneumonia, bronchitis, hypokalaemia, nasopharyngitis, hoarseness, sinusitis, arthralgia and myalgia.
The incidence of the aforementioned side effects, accompanied by the possible incidence of other adverse reactions, would require the utmost precaution in the use of the drug.

Note

SERETIDE ® is a prescription drug.


The information on SERETIDE ® - Salmeterol and Fluticasone published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.


none:  fish zumba-lessons Power supply